EN DE

Textmunication Holdings Inc (KOAN) Fair Value & Analysis

Healthcare · US · Market cap $277K

TH Textmunication Holdings Inc logo Textmunication Holdings Inc KOAN · US
Price$0.0004
Fair Value$0.0003
Upside-25.0%
Quality27/100
Watch Textmunication Holdings Inc for free, get notified when fair value or trend changes. Watch for free
Mixed Growth
Highly profitable · 51.2% net margin
Negative equity (buybacks among others) · negative free cash flow
Trails peers (3/8)
Narrow moat 23/100
Evidence: Low Range $0.0003 – $0.0003 Share as image

Fair value as of: Jul 29, 2026

From 3 valuation models · updated 20 days ago

Share price −20.0% over the past month.

Below-average quality, and screening another 25% overvalued on our models.

What matters now

  • The price sits above even our optimistic bull case ($0.0003). The favourable scenario is already priced in.
  • Weak quality (27/100) and above fair value at the same time, the margin of safety is missing on both counts.
  • Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

$0.5900 $0.0004 Fair Value $0.0003 May 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 29, 2026.

How to read this chart

60‑month range $0.0004 – $0.5900 · the $0.0004 price screens above the $0.0003 fair value. Dashed = 300-day average. As of Jul 29, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Textmunication Holdings Inc (KOAN) currently trades at $0.0004, while our model-based Fair Value estimate is $0.0003, implying the stock looks roughly 25.0% overvalued today. The Quality Score stands at 27/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).

Over the trailing twelve months, Textmunication Holdings Inc generated revenue of $2.2M at a net margin of 51.2%. Net debt stands at $5.3M. Fundamentals as of Jul 29, 2026

For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -25%, KOAN screens cheaper than that median.

Notify me when KOAN reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) $2.2M
Revenue growth (YoY) +353%
Net margin 51.2%
Free cash flow −$1.5M FY2025
Operating margin -76.7%
EPS (TTM) $-0.0100
More key figures
EPS growth (YoY) -74.2%
Net debt $5.3M FY2025

Figures from reported company fundamentals · as of Jul 29, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 27/100

Of which business quality 28 · Market factors (momentum, volatility) 0

Profitability 37
Margins and returns on capital today
Quality Growth 60
Are margins and returns improving?
Cashflow 31
Earnings quality: real cash, not paper profit
Fin. Strength 2
Balance sheet, leverage, solvency risk
Investment 50
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 0
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 0
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Resonate Blends, Inc. engages in the discovery, development, and marketing of products for mankind in the field of regenerative medicine. It focuses on marketing licensed patent-pending natural stem cell mobilizing agents for enhancing individual's ability to mobilize their own adult stem cells from their bone marrow.

Full company description

Resonate Blends, Inc. engages in the discovery, development, and marketing of products for mankind in the field of regenerative medicine. It focuses on marketing licensed patent-pending natural stem cell mobilizing agents for enhancing individual's ability to mobilize their own adult stem cells from their bone marrow. The company also has a license to market a dual acting all-natural diet aid to help control hunger through normal body signals to the brain and stomach. In addition, it is involved in the research and development activities focusing on exploring other areas, such as Secretogues to enhance a person's own growth hormone production and similar natural bioactive formulations to enhance human performance utilizing known body mechanisms without the use of drugs. The company is based in North Bergen, New Jersey.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Textmunication Holdings Inc reported revenue of $1.7M in FY2025 versus $27.0K in FY2021, a compound +181.7%/yr. Reported net income was −$1.7M in FY2025.

Growth Quality 49/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2025)
$1.7M
Latest YoY
−10.2%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+225.3%
Avg. growth/yr (33Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−6.6%
Revenue +181.7%/yr
FY21 $27.0K
FY22 $49.5K
FY23 $16.5K
FY24 $1.9M
FY25 $1.7M
Net income
FY21 −$5.0M
FY22 $2.9M
FY23 −$1.4M
FY24 −$2.1M
FY25 −$1.7M

KOAN screens 25% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Textmunication Holdings Inc Fair Value". https://www.fairvalue-calculator.com/stock/KOAN

Peer Group

Drug Manufacturers - Specialty & Generic · 625 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 27 · Bottom 25%
Fair Value upside −25% · Below median
Return on assets -28% · Bottom 25%
Net margin (TTM) 51% · Top 25%
Operating margin (TTM) -77% · Bottom 25%
Revenue growth 353% · Top 25%

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/S (TTM) 0.12× · Cheaper than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0 · sector 7
FUTURE 100 · sector 20
PAST 0 · sector 24
HEALTH 0 · sector 96
DIVIDEND 0 · sector 32

VALUE 0: the price sits above our fair-value range.

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 29, 2026).

Stock Price Fair Value vs Fair Value
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥53.76 ¥25.94 -52%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,944 ₹989.50 -49%
Divi's Laboratories Limited DIVISLAB ₹8,500 ₹1,932 -77%
Torrent Pharmaceuticals Limited TORNTPHARM ₹4,915 ₹1,163 -76%
PharmaEssentia Corporation 6446 1,440 TWD 233.93 TWD -84%
Cipla Limited CIPLA ₹1,463 ₹1,001 -32%
Zydus Lifesciences Limited ZYDUSLIFE ₹1,167 ₹703.32 -40%
Lupin Limited LUPIN ₹2,281 ₹2,477 +9%
Mankind Pharma Limited MANKIND ₹2,433 ₹983.11 -60%
Dr. Reddy's Laboratories Limited DRREDDY ₹1,200 ₹874.79 -27%

Compare Textmunication Holdings Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Textmunication Holdings Inc (KOAN) overvalued or undervalued?
As of Jul 29, 2026, our model estimates a fair value of $0.0003 versus a price of $0.0004, about −25% (overvalued).
What is the fair value of KOAN?
Our model-based fair value for Textmunication Holdings Inc is $0.0003 (as of Jul 29, 2026), built from audited fundamentals. The current price is $0.0004.
What is the quality score of KOAN?
Textmunication Holdings Inc has a Quality Score of 27/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Textmunication Holdings Inc (KOAN)?
Textmunication Holdings Inc reported trailing-twelve-month revenue of about $2.2M (latest available figure, as of Jul 29, 2026).
What is the net profit margin of KOAN?
The net profit margin of Textmunication Holdings Inc is about 51.2%, meaning it keeps roughly 51.2% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Textmunication Holdings Inc and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.